Drug Target Review

APRIL 5, 2024

Together, these attributes provide a strong foundation for protein expression with enough adaptability to produce much of the commercial and therapeutic protein market. The upfront investment in identifying a high-quality CDMO will pay dividends with a stable, high-quality cell line that companies can feel confident going to market with.

Protein Production 96

Protein Production Protein Expression Bioinformatics Production 96

The Pharma Data

MARCH 8, 2021

The companies today reported findings on one secondary objective from the Phase 2a study, showing a reduction in time (days) to negativity of infectious virus isolation in nasopharyngeal swabs from participants with symptomatic SARS-CoV-2 infection, as determined by isolation in Vero cell line culture. About Molnupiravir.

Trials 69

Trials Virus RNA Research Laboratories 69

The Pharma Data

JUNE 9, 2025

This new monoclonal antibody therapy is designed to prevent lower respiratory tract disease caused by respiratory syncytial virus (RSV) in neonates and infants born during or entering their first RSV season. Food and Drug Administration (FDA) granting approval for ENFLONSIA™ (clesrovimab-cfor).

FDA Approval 40

FDA Approval FDA Hospitals Clinical Trials 40

Drug Target Review

DECEMBER 5, 2024

Challenges of viral capsids in gene therapy efficiency A widely used production method of rAAV vectors requires co-transfection of host cell lines with three plasmids, including one carrying the transgene of interest, one carrying the capsid and replication sequences, and a helper virus to circumvent the inability of rAAV to self-amplify.

Therapies 52

Therapies Virus DNA Compliance 52

The Pharma Data

OCTOBER 28, 2020

In the overall patient group with detectable virus at baseline, the average daily reduction in viral load through day 7 was a 0.36 About REGN-COV2 REGN-COV2 is a combination of two monoclonal antibodies (REGN10933 and REGN10987) and was designed specifically to block infectivity of SARS-CoV-2, the virus that causes COVID-19.

Virus 40

Virus Trials Clinical Trials Production 40

The Pharma Data

JANUARY 6, 2021

ONCR-177, its lead oncolytic herpes simplex virus (oHSV)-based immunotherapy, is in human trials as a monotherapy and in combination with Merck’s Keytruda (pembrolizumab) for a range of solid tumors. At least one other company is developing next-generation oncolytic virus-based immunotherapies. from the market close last Thursday.

Virus 52

Virus FDA Approval Clinical Trials Trials 52

Broad Institute

JULY 11, 2024

Targeted drug treatment leads tumor cells to imitate viral infection By Ari Navetta July 11, 2024 Breadcrumb Home Targeted drug treatment leads tumor cells to imitate viral infection Exploiting "viral mimicry," mIDH1 inhibitors trick tumors into thinking they are infected with a virus.

Treatment 72

Treatment Immune Response Drugs Virus 72

The Pharma Data

JANUARY 11, 2021

The exact origins of the virus remain unclear, but a leading theory is that it was carried by bats and passed to humans through an intermediary species of animal, sold as food or medicine in traditional Chinese “wet markets.” ” Associated Press Article. © 2021 HealthDay. ” Associated Press Article.

Virus 52

Virus Government Marketing Research 52

Drug Target Review

SEPTEMBER 28, 2023

Now, ten years later, I’m still CEO, we’ve raised over $1 billion and we’re on a path to profitability with no plans to go back to the capital markets. For security reasons, at the time COVID-19 had to be grown in BSL-3 labs, which can be dangerous because they were handling the live virus. We look forward to making cloning obsolete.

DNA 116

DNA Organic Chemistry Science Virus 116

The Pharma Data

SEPTEMBER 8, 2021

The two companies have collaborated for more than 20 years to rapidly address critical healthcare needs including biological threats, such as SARS, anthrax, avian influenza virus H5N1, MERS, the novel influenza virus H1N1 swine, Ebola virus, Zika virus and most recently, SARS-CoV-2 virus and its variants.

Virus 52

Virus Assay Development Disease Research 52

The Pharma Data

NOVEMBER 11, 2020

“As an orally bioavailable small molecule with broad antiviral activity, SLV213 could be a valuable treatment to meet today’s urgent need to fight COVID-19 as well other life-threatening infectious diseases, such as Chagas disease, Ebola virus disease, and Nipah virus infection.”. For more information, visit www.selvarx.com.

Treatment 52

Treatment Small Molecule Virus Pharmacokinetics 52

The Pharma Data

SEPTEMBER 5, 2021

It uses a replication-deficient chimpanzee viral vector based on a weakened version of a common cold virus (adenovirus) that causes infections in chimpanzees and contains the genetic material of the SARS-CoV-2 virus spike protein.

Vaccine 52

Vaccine Virus Clinical Trials Trials 52

The Pharma Data

AUGUST 16, 2021

Still, with the continuing threat of the Delta variant and possible emergence of other variants in the future, we must remain vigilant against this highly contagious virus,” said Albert Bourla, Chairman and Chief Executive Officer, Pfizer. We continuously strive to stay at least one step ahead of the virus.

Vaccine 52

Vaccine FDA Virus Immune Response 52

The Pharma Data

DECEMBER 21, 2020

(Nasdaq:BCRX) today announced that data from part 1 of a clinical trial of its broad-spectrum antiviral, galidesivir, showed that galidesivir was safe and generally well tolerated in patients infected with SARS-CoV-2, the virus that causes COVID-19. It is in advanced development for the treatment of Marburg virus disease.

Clinical Trials 52

Clinical Trials Virus RNA Trials 52

The Pharma Data

OCTOBER 31, 2020

” According to Global Data, the global market for influenza antivirals reached 2.34 Currently the market is comprised primarily of the neuraminidase inhibitor oseltamivir and the newly developed endonuclease inhibitor baloxavir. billion USD in 2019 and is estimated to reach 5.03 billion USD by 2026 at a CAGR of 11.5%.

FDA Approval 52

FDA Approval FDA Virus Clinical Development 52

The Pharma Data

JUNE 19, 2025

BT524 is a lyophilized, virus-inactivated fibrinogen concentrate that can be reconstituted and administered rapidly, ensuring a more controlled delivery of the needed clotting protein. If approved, BT524 could compete directly with other fibrinogen concentrates already available in certain markets, such as RiaSTAP (CSL Behring).

Therapies 40

Therapies Trials Clinical Trials Medical Schools 40

The Pharma Data

NOVEMBER 22, 2020

This opens the possibility of having three safe and effective vaccines on the market under emergency use authorization in the coming weeks, which will help with broader distribution and accessibility. When injected into the body, cells churn out the spike protein, which causes the body’s immune system to recognize the virus.

Vaccine 52

Vaccine Virus Trials Regulations 52

The Pharma Data

JULY 28, 2021

It uses a replication-deficient chimpanzee viral vector based on a weakened version of a common cold virus (adenovirus) that causes infections in chimpanzees and contains the genetic material of the SARS-CoV-2 virus spike protein.

Vaccine 52

Vaccine Virus Science Disease 52

The Pharma Data

MARCH 18, 2021

It uses a replication-deficient chimpanzee viral vector based on a weakened version of a common cold virus (adenovirus) that causes infections in chimpanzees and contains the genetic material of the SARS-CoV-2 virus spike protein.

Vaccine 52

Vaccine Virus Regulations Production 52

The Pharma Data

SEPTEMBER 16, 2020

The move is intended to increase flexibility for health labs to make tests available through the market. Matt Fellows. Source link.

FDA 52

FDA Virus Marketing Disease 52

The Pharma Data

MARCH 14, 2021

It uses a replication-deficient chimpanzee viral vector based on a weakened version of a common cold virus (adenovirus) that causes infections in chimpanzees and contains the genetic material of the SARS-CoV-2 virus spike protein.

Vaccine 52

Vaccine Virus Licensing Licensing 52

The Pharma Data

OCTOBER 26, 2020

Hasan Jafri , Chief Medical Officer of Aridis Pharmaceuticals, will be a speaker on a panel entitled “Direct Antivirals and Other Agents Against SARS-CoV2 Virus.” ” Panel: Direct Antivirals and Other Agents Against SARS-CoV2 Virus Date: Wednesday, October 28, 2020 Time: 10:30AM- 11:50AM ET.

Pharmaceuticals 52

Pharmaceuticals Virus Hospitals Clinical Trials 52

The Pharma Data

DECEMBER 10, 2020

In the study, immunization with the hAd5-COVID-19 vaccine inhibited SARS-CoV-2 virus replication in 100% (10 of 10) of Rhesus macaques, with a drop in viral replication starting on the first day of vaccine administration, and undetectable viral levels as early as three to five days post-challenge in most of the animals.

Vaccine 52

Vaccine Immune Response Virus Clinical Trials 52

The Pharma Data

SEPTEMBER 30, 2021

That’s how easy it’s for SARS-CoV-2, the virus that causes COVID-19, to enter your nose. The function of the adjuvant is to market the body’s immune reaction. Breathe in, exhale. But now, we’re one step closer. Navin Varadarajan, University of Houston M.D.

Vaccine 52

Vaccine Disease Immune Response Virus 52

The Pharma Data

SEPTEMBER 2, 2020

The European Commission (EC) has expanded marketing authorisation for Gilead’s Epclusa (sofosbuvir/velpatasvir/sofosbuvir) to include the treatment of children with chronic hepatitis C infection (HCV). The decision allows use of the therapy in the EU in children as young as six years of age.

Clinical Trials 52

Clinical Trials Virus Treatment Therapies 52

The Pharma Data

DECEMBER 15, 2020

positive agreement (sensitivity) and 100% negative agreement (specificity) between results obtained with the Antigen ELISA and those obtained with a real time PCR test for detecting the virus. We strategically partner with customers to enable earlier and more accurate insights supported by deep market knowledge and technical expertise.

Laboratories 52

Laboratories Science Virus Marketing 52

The Pharma Data

AUGUST 18, 2020

REGN-COV2 could provide a much-needed treatment option for people already experiencing symptoms of COVID-19, and also has the potential to prevent infection in people exposed to the virus, thus slowing the spread of the global pandemic. and Roche will be responsible for distribution outside the U.S. “We

Clinical Trials 52

Clinical Trials Virus Trials Treatment 52

The Pharma Data

APRIL 15, 2022

These data reinforce the potential function of a third dose of the vaccine in maintaining high levels of protection against the virus in this age group. The neutralizing GMT against the wild-type virus was 2153 (after three doses), compared to 335 after two doses.

Immune Response 52

Immune Response Vaccine Clinical Trials Virus 52

The Pharma Data

NOVEMBER 17, 2021

It uses a replication-deficient chimpanzee viral vector based on a weakened version of a common cold virus (adenovirus) that causes infections in chimpanzees and contains the genetic material of the SARS-CoV-2 virus spike protein.

Vaccine 52

Vaccine Clinical Trials Virus Licensing 52

The Pharma Data

JANUARY 29, 2021

29 January 2021 — AstraZeneca’s COVID-19 vaccine has been recommended for conditional marketing authorisation (CMA) in the European Union (EU) for active immunisation to prevent COVID-19 caused by SARS-CoV-2, in individuals 18 years of age and older.

Vaccine 52

Vaccine Clinical Trials Virus Trials 52

The Pharma Data

JANUARY 29, 2021

29 January 2021 — AstraZeneca’s COVID-19 vaccine has been granted a conditional marketing authorisation (CMA) in the European Union (EU) for active immunisation to prevent COVID-19 caused by SARS-CoV-2, in individuals 18 years of age and older.

Vaccine 52

Vaccine Clinical Trials Virus Trials 52

The Pharma Data

NOVEMBER 23, 2020

It is an mRNA vaccine that codes for the virus’s spike protein and is encapsulated in a lipid nanoparticle. Once injected, the cells churn out the spike protein, triggering the body’s immune system to recognize the virus. Russia’s Gamaleya research institute appears to be focused on potentially marketing their vaccine worldwide.

Vaccine 52

Vaccine Virus Immune Response Trials 52

The Pharma Data

JANUARY 14, 2021

That includes interviewing people at area hospitals and from the Southwest China Wholesale Seafood Market suspected of being where the virus jumped from animals into humans, CBS News reported. The team will start work immediately to determine how Wuhan became the world’s first COVID-19 epicenter, the WHO said.

Government 52

Government Virus Hospitals International 52

The Pharma Data

JANUARY 21, 2021

Cabotegravir is a ViiV product marketed as Cabenuva, and rilpivirine is a Janssen product with a brand name Edurant. While much more remains to be done to make HIV history, today’s milestone reminds us how far medical innovation has come since the first reported cases of the virus almost 40 years ago.”. Most Read Today. Source link.

FDA Approval 52

FDA Approval Treatment FDA Clinical Trials 52

The Pharma Data

DECEMBER 31, 2020

a publicly-listed company investing in blockchain technology solutions for capital markets and other sectors that can benefit from tokenization. Stetsenko is a financier and venture capitalist who is acting chief executive officer of CRG Finance AG, a private venture capital firm in Switzerland. He is currently the CEO of BlockchainK2 Corp.,

Engineering 52

Engineering Pharmaceuticals Virus Clinical Development 52

The Pharma Data

FEBRUARY 24, 2022

Medicago, a biopharmaceutical company headquartered in Quebec City, and GlaxoSmithKline (GSK) today announced that Health Canada has granted approval for COVIFENZ®, COVID-19 vaccine, (plant-based virus-like particles [VLP], recombinant, adjuvanted). This vaccine is indicated for active immunization to prevent coronavirus disease 2019 (COVID?19)

Vaccine 52

Vaccine Virus Government Disease 52

The Pharma Data

DECEMBER 14, 2020

When injected into the body, the mRNA enters the cells, causing the cells to churn out the spike molecule which trains the body’s immune system to attack the virus if it encounters it. They had also been partnered with the NIH on bringing mRNA vaccines to market. The mRNA is encapsulated in a tiny fat blob called a nanolipid particle.

Vaccine 52

Vaccine FDA Virus Government 52